Beta blockers and insomnia
Pro Research Analysisby 
Searched over 200M research papers
Beta Blockers and Insomnia: Prevalence and Risk Factors
Several studies have found that beta-blockers can be associated with insomnia and other sleep disturbances, though the risk varies depending on the specific drug and its properties. Patients taking beta-blockers report higher rates of insomnia compared to those not on these medications, with some studies showing a significant increase in insomnia symptoms among beta-blocker users 1246. However, not all research agrees on the extent of this risk, and some controlled trials suggest the effect may be less pronounced than previously thought .
Mechanisms: Melatonin Suppression and CNS Effects
Beta-blockers are known to suppress the production of melatonin, a hormone that regulates sleep-wake cycles. This suppression is believed to contribute to the development of insomnia in patients taking these medications 45. Long-term use of beta-blockers can reduce melatonin synthesis by up to 50%, increasing the risk of sleep disturbances, especially in individuals with already low melatonin levels . Additionally, beta-blockers with high lipophilicity, such as propranolol, are more likely to cross the blood-brain barrier and cause central nervous system side effects, including insomnia, vivid dreams, and nightmares 268.
Differences Among Beta Blockers: Selectivity and Lipophilicity
The risk of insomnia is not the same for all beta-blockers. Drugs that are more selective for beta-1 receptors and have lower lipophilicity, such as bisoprolol and atenolol, are associated with a lower risk of insomnia compared to non-selective and highly lipophilic beta-blockers like propranolol 268. Studies have shown that patients using bisoprolol or atenolol have the lowest risk of insomnia, while those on propranolol have the highest 28. This difference is likely due to the ability of lipophilic beta-blockers to enter the brain more easily and affect sleep regulation 68.
Clinical Impact and Management
While some studies report a higher incidence of insomnia and sleep disturbances in patients taking beta-blockers, others suggest that the overall risk may be overstated, with many symptoms also occurring in patients taking placebo . Nonetheless, for patients who do experience sleep problems, melatonin supplementation has been shown to significantly improve sleep quality, increase total sleep time, and reduce the time it takes to fall asleep, without causing rebound insomnia after discontinuation . This suggests that melatonin may be a useful countermeasure for beta-blocker-induced insomnia.
Conclusion
Beta-blockers can increase the risk of insomnia, particularly those that are non-selective and highly lipophilic. The suppression of melatonin production is a key mechanism behind this side effect. However, the risk varies among different beta-blockers, and not all patients are affected. For those who do experience sleep disturbances, melatonin supplementation may offer significant relief. Overall, clinicians should consider the type of beta-blocker and individual patient risk factors when addressing insomnia in patients on these medications.
Sources and full results
Most relevant research papers on this topic
Side-effects of beta-blockers assessed using visual analogue scales.
Beta-blockers may cause higher symptom scores for tired legs, cold digits, insomnia, and lack of well-being, but no significant differences were found between different beta-blockers.
Risk of insomnia attributable to β-blockers in elderly patients with newly diagnosed hypertension.
Bisoprolol and atenolol are associated with the lowest risk of insomnia in elderly patients with newly diagnosed hypertension, while propranolol has a higher risk.
[The effect of long-term beta-blockers on melatonin secretion, sleep quality, and vascular brain damage].
Long-term beta-blocker administration reduces melatonin synthesis by 50%, increasing the risk for insomnia and metabolic disorders in patients with cardiovascular diseases.
Psychiatric adverse events of calcium channel blockers – protocol for a systematic review and meta-analysis
This study aims to review and meta-analyze the relationship between calcium channel blockers and psychiatric adverse events, including depression, anorexia, insomnia, and anxiety, in patients receiving these drugs for cardiovascular or non-cardiovascular indications.
DOI